Earnings ·
Zai Lab reports Q3 revenue of $108.2M and raises $241.2M via private placement
ZLABZai Lab Ltd
Zai Lab Limited reported third-quarter 2026 total revenues of $108.2 million, a decrease from $116.1 million in the prior-year period, driven by a decline in OPTUNE sales partially offset by growth in NUZYRA and the new KarXT launch. The company posted a net loss of $46.1 million, or $0.04 per ADS, compared to a $36.0 million loss in 2025, with the increase largely attributed to $13.6 million in inventory write-downs. Additionally, Zai Lab completed a private placement of 11,340,000 American Depositary Shares at $22.04 per share, raising approximately $241.2 million in net proceeds to fund pipeline development and working capital. The company anticipates major clinical catalysts in 2027 for its zoci program in small cell lung cancer and ZL-1503 in atopic dermatitis. Zai Lab Limited is an innovation-driven, global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines in oncology, immunology, neuroscience, and infectious disease.